Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement

BACKGROUND: Leptomeningeal inflammation is associated with increased cortical damage and worse clinical outcomes in MS. It may be detected on contrast-enhanced T2-FLAIR imaging as focal leptomeningeal contrast-enhancement (LME). OBJECTIVE: To assess the safety of intrathecal (IT) rituximab in progre...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Mult Scler Relat Disord
Glavni autori: Bhargava, Pavan, Wicken, Cassie, Smith, Matthew D, Strowd, Roy E., Cortese, Irene, Reich, Daniel S, Calabresi, Peter A, Mowry, Ellen M
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325522/
https://ncbi.nlm.nih.gov/pubmed/30771580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2019.02.013
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items